Synapse - Works

Results (115370)

Clonal hematopoiesis and risk of incident lung cancer

Journal Article

Tian, R.; Wiley, B.; Liu, J.; Zong, X.; Truong, B; Zhao, S.; Uddin, M. D. M.; Niroula, A.; Miller, C. A.; Mukherjee, S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO Living Guideline, version 2022.2

Guidelines

Owen, D. H.; Singh, N.; Ismaila, N.; Blanchard, E.; Celano, P.; Florez, N.; Jain, D.; Leighl, N. B.; Mamdani, H.; Masters, G.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up

Journal Article

Martin, T.; Usmani, S. Z.; Berdeja, J. G.; Agha, M.; Cohen, A. D.; Hari, P.; Avigan, D.; Deol, A.; Htut, M.; Lesokhin, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Physical activity in stage III colon cancer: CALGB/SWOG 80702 (Alliance)

Journal Article

Brown, J. C.; Ma, C.; Shi, Q.; Fuchs, C. S.; Meyer, J.; Niedzwiecki, D.; Zemla, T.; Couture, F.; Kuebler, P.; Kumar, P.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Meeting Abstract

Iyer, G.; Demeure, M. J.; Deming, D. A.; Federman, N.; McKean, M.; Lee, E. K.; Spira, A. I.; Kwiatkowski, D. J.; Hussein, M. A.; Gordon, E. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001)

Meeting Abstract

Powles, T.; Yu, E. Y.; Iyer, G.; Campbell, M. T.; Loriot, Y.; De Santis, M.; O'Donnell, P. H.; Burgess, E. F.; Necchi, A.; Krieger, L. E. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Choueiri, T. K.; Bedke, J.; Karam, J. A.; McKay, R. R.; Motzer, R. J.; Pal, S. M.; Suárez, C.; Uzzo, R.; Liu, H.; Burgents, J. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer

Meeting Abstract

Patel, A. B.; Anadkat, M. J.; Marathe, O. S.; Webb, M. L.; Tyler, R. C.; Zhang, W.; Wu, C.; Ju, J.; Tang, H.; Luo, J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)

Meeting Abstract

Zebic, D.; Stockler, M. R.; Martin, A. J.; Pashankar, F. D.; Tran, B.; Mazhar, D.; Huddart, R. A.; Wheater, M.; Walpole, E. T.; Dunwoodie, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save